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salmeterol/fluticasone, beclametasone/formoterol, budesonide/formoterol (free 
adjustable combination) and conventional best practice. METHODS: For 
construction of pharmacoeconomic model a set of comparative randomised 
controlled trials for each therapeutic alternative were identified. From them data 
on clinical effectiveness in form of asthma exacerbations avoided for 1 patient-
year were extracted. The analysis was conducted from the perspective of 
Russian health care system. Respectively the cost of the following resources was 
accounted: alternative compared, concomitant pharmacotherapy, cost of 
hospitalizations, cost of ambulkatory visits. Analysis was performed in the form 
of cost-effectiveness analysis the exacerbation prevented being the measure of 
effectiveness. RESULTS: The data of the research illustrates that 
budesonide/formoterol maintenance and reliever therapy for asthma patients 
provides a significant health improvement from the perspective of preventing 
exacerbations. Simultaneosly budesonide/formoterol maintenance and reliever 
therapy demonstrates better cost-effectiveness than alternatives compared. The 
CER index in relation to cost of asthma control during the year (absence  
of exacerbations) for budesonide/formoterol maintenance and reliever therapy 
was 147785 rub. respective figures for salmeterol/fluticasone, beclametasone/ 
formoterol, budesonide/formoterol (free adjustable combination) and 
conventional best practice were 383622 rub., 169245 rub., 227592 rub., 219233 
rub., respectively. CONCLUSIONS: Budesonide/formoterol fixed combination for 
maintenance and reliever therapy turned to be cost-effective therapeutic 
alternative for asthma control in adult patients in conditions of Russian health 
care system.  
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OBJECTIVES: Acute exacerbations of chronic bronchitis (AECB) are a leading 
cause of morbi-mortality and medical resources consumption. This study  
was aimed to estimate the economic and health consequences of first line 
antibiotics in the management of AECB and it´s recurrences, under the setting of 
a representative Mexican health care institution. METHODS: Two models  
were developed: a decision tree for acute events (tree month horizon) and a two-
state, one-quarter cycle Markov for recurrences (one year horizon). The 
competing alternatives (listed in the national formulary) were: moxifloxacin 400 
mg/day, levofloxacin 500 mg/day, ceftriaxone 1000 mg/day, clarithromycin 1000 
mg/day, cefuroxime 1000 mg/day and, not listed in the national formulary, 
gemifloxacin 320 mg/day. The clinical success rate and months free of 
recurrences (effectiveness measures) were extracted from international 
literature. Resource use was extracted from 117 clinical files (adult patients) 
treated at Instituto Mexicano del Seguro Social (IMSS).The cost of antibiotics 
were extracted from IMSS´s sources (except of gemifloxacin, provided by the 
manufacturer); the unit cost of physician visits, diagnostic tests, emergency 
room, in-patient, intensive care unit were the official for IMSS. Costs are 
expressed in 2012 U$. One-way sensitivity analysis was performed. RESULTS: 
The clinical success rates were between 97.5% (gemifloxacin) and 83.1% 
(cefuroxime), the costs per patient-per AECB were proportional: $3,375.6 
(gemifloxacin) and $4825.1% (cefuroxime), gemifloxacin dominated progressively 
ceftriaxone, moxifloxacin, levofloxacin, clarithromycin and cefuroxime. 
Regarding AECB recurrences, clarithromycin represented the highest cost and 
lowest time free of recurrence: $8198.99 and 10.28 months, respectively, whereas 
gemifloxacin represented the opposite: $3,325.73 and 11.015 months, 
respectively. The length of stay were between 6.22 (gemifloxacin) and 10.3 days 
(cefuroxime). The results were robust to +10% acquisition cost, +5% adverse 
events incidence and -5% clinical success rate for gemifloxacin. CONCLUSIONS: 
At IMSS setting, gemifloxacin is an alternative that would promote savings in the 
treatment of AECB and it´s recurrences.  
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OBJECTIVES: To evaluate the cost effectiveness of long-term therapy with high flow 
humidified air supplemented with oxygen as required at 37°C delivered through 
nasal cannulae (long term humidification therapy; LTHT) for patients with 
moderate or severe COPD or bronchiectasis. METHODS: The source was a 12-month 
clinical trial showing that LTHT at a mean duration of 1.6 hours per day reduced 
exacerbation days and improved quality of life assessed by the St. George’s 
Respiratory Questionnaire compared to usual care alone. Resources included the 
LTHT intervention equipment and consumables, relevant hospital admissions, 
general practitioner consultations, Emergency Care presentations and 
pharmaceuticals. Details of consultations and medication usage were obtained 
from patient diaries and hospital admissions from retrospective administrative 
records. Utility values were obtained indirectly from the St Georges Respiratory 
Questionnaire using a published algorithm. The ICUR was estimated over the 
lifetime of the device (5 years) using the bootstrap method with 5000 replications. 
Future costs and benefits were discounted at 3.5% per annum. RESULTS: The 
incremental health state utility over 12 months was estimated at +0.084 (95% CI 
0.003-0.165). Annual costs excluding the intervention were NZ$2329 (95%CI $1249, 
$3409) for the treatment group and NZ$3477 ($712, $6241) for the control group 
(nsd). With the LTHT intervention costed at $10,461 over the lifetime of the device (5 
years) the cost per QALY was NZ$15,615 (95%CI $15,521, $15,709). At a willingness to 
pay (WTP) threshold of NZ$30,000, the probability of LTHT being cost effective was 
89% and at a WTP threshold of $20,000 it was 71%, ranging from 64% to 77% as the 
5-year cost of LTHT equipment and running costs was varied by ±20%. 
CONCLUSIONS: Long term humidification therapy for moderate to severe COPD or 
bronchiectasis is as cost effective as most new pharmaceuticals that are 
reimbursed by the New Zealand government.  
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INTRODUCTION: Childhood asthma is a major public health problem in 
Colombia as in many other countries. In patients entering the second line 
therapy, options in the 5-11 years old category are increase corticosteroids, add 
LABA or add LTRA. In under five years old adding LABA is not an option. There 
are differences in cost and efficacy between these options, to address this issue 
an economic evaluation was done in the context of the National Colombian 
Clinical Practice Guidelines Programme in collaboration with the Colombian 
Pediatric Pneumonology Association. OBJECTIVES: To evaluate the cost 
effectiveness of the second line asthma therapy options in pediatric patients in 
Colombia. METHODS: A Markov model was developed including the following 
health states: controlled asthma, uncontrolled asthma, ambulatory exacerbation, 
exacerbation with hospitalization and therapeutic failure. A restringed social 
perspective was used (health system + out of pocket expenses) with a 3 months 
time horizon. Transition probabilities and utility estimates were derived from 
international literature and validated by a Delphi panel with local Colombian 
experts. Costs were provided by the Colombian MoH. A deterministic and 
probabilistic sensitivity analysis was performed. RESULTS: The LTRA option was 
dominated, being more expensive and less efficacious than increasing 
corticosteroids in both age categories. In the 5-11 years old the ICER comparing 
LABA with corticosteroids was 4.366.343 Colombian pesos (COP) per quality 
adjusted life week (QALW) gained. This ICER is far above the 634.000 COP per 
QALW estimated for a 3 GDP threshold. In the sensitivity analysis these results 
probed to be robust being necessary a 4.400.000 COP per QALW of willingness to 
pay for the LRTA option to start being cost effective. CONCLUSIONS: Increasing 
corticosteroids was the most cost effective option in asthmatic pediatric 
population in Colombia compared to LABA, being LRTA dominated or far above 
the Colombian thresholds.  
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OBJECTIVES: Despite the known importance of regular use of inhaled 
corticosteroids (ICS) for asthma control, there is a dearth of adherence literature 
from India. The study aims were to (i) evaluate patients’ self-reported adherence 
to ICS therapy, (ii) identify possible reasons for non-adherence, and (iii) identify 
possible correlations between ICS adherence, medicine beliefs and socio-
demographic factors of asthma patients. METHODS: Adults with previously 
diagnosed asthma (n=200) presenting to the emergency room (March 2009-
December 2009) of a public chest hospital in Delhi for asthma exacerbation 
completed an interviewer-administered questionnaire on socio-demographics, 
clinical history, self-reported adherence, beliefs about causes of disease, 
medicine beliefs and medication adherence after stabilization of their condition. 
RESULTS: Study sample had 51.5% patients in the age group of 30-40 years, 54.0% 
females, 10.0% illiterate, and 62.5% patients earning less than INR 10,000/month 
($185/month). The mean duration of registration with the study hospital was 
5.4±4.4 years and all were prescribed ICS treatment. Self-report on adherence: 
49% took medicines even without symptoms; 91.0% reported they forgot to take 
their medicine “some or lot of times”; 84.0% avoided medicines “some of the 
times”. Important reasons for avoiding medicines were no symptoms (59.5%), 
cost (34.5%), fear of getting dependent (29%), side effects (17%) and social 
inhibition (14.5%). Correlation between self-reported adherence and 
demographic factors, such as age, sex, education and income was calculated. 
The commonly endorsed causes for asthma were pollution (33.5%), poor medical 
care in the past (15.5%), heredity (8.5%), cold climate (7.5%), and diet (5.5%). Non-
adherent behaviors were associated with doubts about the necessity of 
medication and concerns about its potential side effects with long-term use (r=-
0.299, p<0.001). CONCLUSIONS: Adherence to ICS therapy is poor and many 
factors modulate adherence to therapy. These findings lend preliminary support 
for an extended self-regulatory model of treatment adherence, which 
incorporates beliefs about treatment.  
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